Thyme Care, founded in 2020, raised a $97 million Series D in 2025, giving it a $1.5 billion valuation. The company has raised ~$280 million to date from investors including a16z and Concord Health Partners. Thyme Care delivers personalized oncology care using data driven treatment plans, predictive analytics, and coordinated care teams. Serving thousands of patients, the platform integrates diagnostics, therapy guidance, and continuous monitoring to optimize outcomes. With robust funding and clinical capabilities, Thyme Care is positioned to scale personalized cancer care across the United States.